{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:10:52Z","timestamp":1790820652607,"version":"4.1.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jidinnovations.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JID Innovations"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.xjidi.2022.100156","type":"journal-article","created":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T13:33:03Z","timestamp":1662557583000},"page":"100156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Safety and Efficacy of Ritlecitinib and Brepocitinib in Alopecia Areata: Results from the Crossover Open-Label Extension of the ALLEGRO Phase 2a Trial"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4576-4616","authenticated-orcid":false,"given":"Brett","family":"King","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9363-324X","authenticated-orcid":false,"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4869-3240","authenticated-orcid":false,"given":"Elena","family":"Peeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2982-2940","authenticated-orcid":false,"given":"Anindita","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7358-8632","authenticated-orcid":false,"given":"Linda","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4908-0174","authenticated-orcid":false,"given":"Hua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8420-6994","authenticated-orcid":false,"given":"Lori Ann","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9569-4284","authenticated-orcid":false,"given":"Michael S.","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6751-1428","authenticated-orcid":false,"given":"Rodney","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xjidi.2022.100156_bib1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/ajd.12941","article-title":"Treatment of alopecia areata: an Australian expert consensus statement","volume":"60","author":"Cranwell","year":"2019","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.xjidi.2022.100156_bib2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41598-021-04075-0","article-title":"Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study","volume":"12","author":"Ebina","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.xjidi.2022.100156_bib3","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","article-title":"A\u00a0phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in\u00a0alopecia areata: 24-week results","volume":"85","author":"King","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2022.100156_bib4","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jaad.2019.08.032","article-title":"Epidemiology of alopecia areata, ophiasis, totalis, and universalis: a systematic review and meta-analysis","volume":"82","author":"Lee","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2022.100156_bib5","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jaad.2018.01.048","article-title":"Alopecia areata is associated with impaired health-related quality of life: a survey of affected adults and children and their families","volume":"79","author":"Liu","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2022.100156_bib6","article-title":"Association between alopecia areata, anxiety, and depression: a systematic review and meta-analysis","author":"Okhovat","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2022.100156_bib7","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jaad.2003.09.032","article-title":"Alopecia areata investigational assessment guidelines--part II. National Alopecia Areata Foundation","volume":"51","author":"Olsen","year":"2004","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2022.100156_bib8","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jaad.2021.12.008","article-title":"Maintenance, withdrawal and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial","volume":"87","author":"Peeva","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2022.100156_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.11","article-title":"Alopecia areata","volume":"3","author":"Pratt","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.xjidi.2022.100156_bib10","doi-asserted-by":"crossref","first-page":"453","DOI":"10.55563\/clinexprheumatol\/cbanza","article-title":"Efficacy and safety of switching Jak inhibitors in rheumatoid arthritis: an observational study","volume":"39","author":"Retuerto","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.xjidi.2022.100156_bib11","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.2147\/DDDT.S172638","article-title":"Role of Janus kinase inhibitors in the treatment of alopecia areata","volume":"12","author":"Triyangkulsri","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.xjidi.2022.100156_bib12","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.jid.2018.05.027","article-title":"JAK inhibitors for treatment of alopecia areata","volume":"138","author":"Wang","year":"2018","journal-title":"J\u00a0Invest Dermatol"}],"container-title":["JID Innovations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026722000649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026722000649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T08:03:19Z","timestamp":1763020999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667026722000649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S2667026722000649"],"URL":"https:\/\/doi.org\/10.1016\/j.xjidi.2022.100156","relation":{},"ISSN":["2667-0267"],"issn-type":[{"value":"2667-0267","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Efficacy of Ritlecitinib and Brepocitinib in Alopecia Areata: Results from the Crossover Open-Label Extension of the ALLEGRO Phase 2a Trial","name":"articletitle","label":"Article Title"},{"value":"JID Innovations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xjidi.2022.100156","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}],"article-number":"100156"}}